Infektionsimmunologi / Adjuvans
My research focuses on how vaccine excipients/adjuvants can help vaccines to provide optimal protection. This involves studying how adjuvants direct the immune response in relation to the specific disease one aims to develop a vaccine against, as well as the development of new types of adjuvants.
- Post Doc in the department of Infectious Disease Immunology, Center for Vaccine Research
K Wørzner, J Hvannastein, ST Schmidt, C Foged, I Rosenkrands, GK Pedersen and D Christensen. Adsorption of protein antigen to the cationic liposome adjuvant CAF®01 is required for induction of Th1 and Th17 responses but not for antibody induction. Eur. J. Pharm Biopharm, 2021
K Wørzner, DJ Sheward, ST Schmidt, L Hanke, J Zimmermann, G McInerney, GBK Hedestam, B Murrell, D Christensen and GK Pedersen. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. EBioMedicine, 2021
GK Pedersen, K Wørzner, P Andersen and D Christensen. Vaccine Adjuvants Differentially Affect Kinetics of Antibody and Germinal Center Responses. Front Immunol, 2020
ST Schmidt, CL Olsen, H Franzyk, K Wørzner, KS Korsholm, T Rades, P Andersen, C Foged and D Christensen. Comparison of two different PEGylation strategies for the liposomal adjuvant CAF09: Towards induction of CTL responses upon subcutaneous vaccine administration. Eur. J. Pharm Biopharm, 2019
All publications: Katharina Wørzners bibliography